ERBB2 and breast cancer: Furthermore, whereas HRG can reverse the antitumor effects of lapatinib in parental HER2+ breast cancer cells (Additional file 8) [44-46], the antitumor effects of neratinib in parental HER2+ breast cancer cells are more resistant to HRG (Additional file 8).